Prospective Registry of Multiplex Testing (PROMPT)

Status:	Recruiting
Healthy:	No
Age Range:	18 - Any
Updated:	3/2/2019
Start Date:	January 2016
End Date:	January 2020
Contact:	Mark Robson, MD
Phone:	646-888-4058

Prospective Registry of Multiplex Testing (PROMPT): Phase II

This study is being done to learn more about how changes in certain genes may be linked to
cancer. Some people with cancer got their disease because they inherited an abnormal
(mutated) gene.

The researchers of this study want to better understand the risks that are linked to genetic
changes in these less well-studied genes. By understanding these risks, we believe that
doctors will be able to give better advice to families with mutations in these genes.

PROMPT (Prospective Registry of Multiplex Testing) is an Internet-based, patient-directed
ascertainment study. It is a partnership between Memorial Sloan Kettering, University of
Pennsylvania, Mayo Clinic, and Dana Farber Cancer Institute in collaboration with Ambry
Genetics, GeneDx, Myriad Genetics, Pathway Genomics, and Quest Laboratories (5 laboratories
providing multiplex panel testing commercially).

Inclusion Criteria:

- Individual with deleterious (pathogenic) or likely deleterious (likely pathogenic)
mutation in a cancer susceptibility gene OR

- Individual with a variant of uncertain significance (VUS) in a cancer susceptibility
gene OR

- Family members, either tested or not tested, who are part of a family known to be
transmitting a deleterious or likely deleterious mutation or a variant of uncertain
significance in a cancer predisposition gene

Exclusion Criteria:

- Inability or refusal to participate in consent discussion

- Subject is less than 18 years old

We found this trial at

sites

Memorial Sloan-Kettering Cancer Center at Commack

650 Commack Rd
Commack, New York 11725

(631) 623-4000